Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
17
|
pubmed:dateCreated |
1990-9-27
|
pubmed:abstractText |
In the perspective of increasing the clinical potential of ricin A chain immunotoxins (RTA-ITs), perhexiline (Pex) and four structural analogues (Pex 2, Pex 3, Pex 7, and Pex 11) were evaluated for their ability to enhance RTA-IT activity in vitro. Only perhexiline significantly enhanced the cytotoxic activity of anti-CD5 RTA-ITs, T101 and T101-F(ab')2, on CEM III cell line (30- to 2000-fold), and of anti-HLA-DR RTA-IT, HNC-241, on both RAJI cell line (greater than 100-fold) and two immortalized cell lines originating from patients suffering from B-cell chronic lymphocytic leukemia, EHEB and FS2 D5 (10-fold). On 16 consecutive fresh B-cell chronic lymphocytic leukemia cell samples, significant T101-F(ab')2 RTA-IT and HNC-241 RTA-IT enhancement was observed with perhexiline which was comparable to that of NH4Cl and monensin. Perhexiline almost completely blocked RTA-IT intracellular degradation and profoundly modified its routing. These observations were linked to perhexiline-induced lipidosis via inhibition of sphingomyelinase activity. In conclusion, since the concentrations used are relevant with the pharmacokinetics of this agent, perhexiline appears to be a promising agent for in vivo enhancement of ricin A chain immunotoxins.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Ammonium Chloride,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Immunotoxins,
http://linkedlifedata.com/resource/pubmed/chemical/Monensin,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Perhexiline,
http://linkedlifedata.com/resource/pubmed/chemical/Ricin,
http://linkedlifedata.com/resource/pubmed/chemical/Verapamil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
50
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5558-66
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2386962-Ammonium Chloride,
pubmed-meshheading:2386962-Antibodies, Monoclonal,
pubmed-meshheading:2386962-Cell Line,
pubmed-meshheading:2386962-Humans,
pubmed-meshheading:2386962-Immunotoxins,
pubmed-meshheading:2386962-Kinetics,
pubmed-meshheading:2386962-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:2386962-Monensin,
pubmed-meshheading:2386962-Neoplasm Proteins,
pubmed-meshheading:2386962-Perhexiline,
pubmed-meshheading:2386962-Ricin,
pubmed-meshheading:2386962-Tumor Cells, Cultured,
pubmed-meshheading:2386962-Verapamil
|
pubmed:year |
1990
|
pubmed:articleTitle |
Enhancement of ricin A chain immunotoxin activity by perhexiline on established and fresh leukemic cells.
|
pubmed:affiliation |
Laboratoire de Pharmacologie et de Toxicologie Fondamentales, CNRS, Toulouse, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|